SCIENTIFIC RIGOR: This article is based on two research studies with histological biopsy published in Aesthetic Plastic Surgery (2022) and Aesthetic Surgery Journal (2025), conducted by Dr. Gutiérrez-Ontalvilla at the Hospital La Fe in Valencia and the Nixarian Institute. This is not advertising. It is science with biopsy.
DIRECT RESPONSE
For vulvar lichen sclerosus, corticosteroids control symptoms but do not repair damaged tissue. The Liquenia-SVF protocol — nanofat plus the patient’s own mesenchymal stem cells (SVF) — has demonstrated in two clinical studies with histological biopsy that it reverses fibrosis, increases vascularization, and reduces autoimmune inflammation in more than 65% of patients at 12 months. Zero serious adverse events.
If clobetasol is no longer enough, this article changes what you believe is possible
You have been applying the ointment for a while. Sometimes it improves. Sometimes the itching returns in the early hours of the morning. You have asked at the clinic and been told that “you have to live with this.” Intimate relationships are no longer what they were. The skin that was once yours now hurts, itches, burns, and limits you. If you recognize this, keep reading.
Vulvar lichen sclerosus is a chronic inflammatory disease with an autoimmune component. Corticosteroids remain the correct — and necessary — first step in its treatment. However, 30–40% of women do not respond satisfactorily to clobetasol. And for them, for decades, there has been no real second option.
That has changed. Two clinical studies published in international scientific journals have documented, with histological biopsy before and after, that vulvar tissue affected by lichen sclerosus can regenerate. Not just improve: regenerate. That is exactly what this article will explain to you, with real data and without empty promises.
“The Lichen-SVF protocol acts on the underlying pathological alterations. Unlike corticosteroids, which suppress symptoms without reversing tissue damage.”
Gutiérrez-Ontalvilla et al., Aesthetic Surgery Journal, 2025
How corticosteroids and the Liquenia-SVF protocol act on vulvar tissue
Topical corticosteroids: effective on symptoms, silent on tissue
Clobetasol propionate 0.05% is the first-line treatment recommended by all international clinical guidelines. It acts by suppressing the local inflammatory response: it reduces itching and burning and slows the visible progression of lesions.
Its limitation is conceptual, not dosage-related: it acts on the symptom, not the cause. It does not repair tissue damaged by years of autoimmune inflammation. It does not reverse fibrosis. It does not regenerate lost blood vessels. And prolonged use can thin the vulvar epithelium — an effect documented by Barnes et al. (2015) — creating a paradox: the same treatment that stops atrophy can accelerate it if used without proper supervision.
The Liquenia-SVF protocol: stem cells from your own body to repair tissue
The Liquenia-SVF protocol uses the patient’s own adipose tissue — extracted from the abdomen or inner thigh — to obtain two injectable components in the same session:
Nanofat
Adipose tissue mechanically processed to obtain a very fine suspension rich in growth factors and stromal stem cells. It is injected into the superficial dermis of the entire vulvar and perianal area, providing regenerative signals directly to the damaged tissue.
SVF — Stromal Vascular Fraction
This contains the mesenchymal stem cells, along with angiogenic factors and anti-inflammatory mediators. It is obtained by mechanical microfragmentation, without chemical enzymes. Its function: to modulate the autoimmune response, stimulate new blood vessels, and reverse the fibrosis characteristic of advanced lichen sclerosus.
The difference with corticosteroids is not one of intensity: it is one of mechanism. Corticosteroids put out the fire. The Liquenia-SVF protocol rebuilds what the fire destroyed.
Corticosteroids vs. Liquenia-SVF protocol: complete comparison
Table 1. Comparative overview of both treatments in vulvar lichen sclerosus.
| Comparison criterion | Corticosteroids (clobetasol) | Liquenia-SVF Protocol |
|---|---|---|
| Mechanism of action | Suppression of local inflammation (symptomatic) | Tissue regeneration + immune modulation (on the cause) |
| Type of procedure | Topical, daily application at home | Session in operating room under general anesthesia |
| Patient’s own material | ✗ No | ✓ 100% Yes |
| First line according to clinical guidelines | ✓ Yes | Second line: for non-responders to clobetasol |
| Reduces itching and burning | ✓ Effective in most | ✓ 77% reduction |
| Improves fissures and pallor / white patches | ⚠ Little documented improvement | ✓ Significant improvement |
| Reverses stromal fibrosis | ✗ No | ✓ Yes — significant reduction |
| Increases microvascular density | ✗ No | ✓ Yes — significant increase |
| Reduces CD3+ T lymphocytes (autoimmunity) | ✗ No | ✓ Yes — significant reduction |
| Resolution of severe atrophy of labia minora | ✗ No | ✗ Neither — an honest limit of both |
| Improves quality of life (Skindex-29) | ⚠ No statistical significance | ✓ Significant improvement |
| Serious adverse events | ⚠ Epidermal atrophy with prolonged use | ✓ None in two published studies |
| Number of sessions required | Indefinite chronic use | 1–2 sessions (maintenance data under study) |
Clinical results of the Liquenia-SVF protocol: data from two studies with biopsy
Two independent clinical studies have documented in biopsy what no treatment had demonstrated before in vulvar lichen sclerosus: that fibrosed tissue can recover its structure, blood vessels, and function.
Study 1 (2022) — Hospital La Fe de Valencia, IisLaFe
19 patients with moderate-severe vulvar lichen sclerosus non-responsive to clobetasol. Two infiltrations of nanofat + PRP, 12-month follow-up.
Reduction in itching, burning, and pain
Inflammatory cells in biopsy
Quality of Life (Skindex-29) p = 0.004
Study 2 (2025) — Nixarian Institute, Valencia
18 patients with moderate-severe vulvar lichen sclerosus resistant to conventional treatments. A single session of the complete Liquenia-SVF protocol. 12-month follow-up.
Reduction in total symptoms (CSS) p = 0.0136
Reduction in clinical signs p = 0.0014
Reduction in itching (5D Itch) p = 0.0025
Table 2. Comparative clinical results between corticosteroids and Liquenia-SVF protocol at 12 months.
| Parameter evaluated | Corticosteroids | Liquenia-SVF Protocol |
|---|---|---|
| Reduction in itching (5D Itch scale / VAS) | No significant improvement | −66% at 12 months |
| Reduction in burning and pain | No significant improvement | −77% at 12 months |
| Improvement in dyspareunia | No significant change | Positive trend |
| Reduction in fissures (CSS signs) | No significant change | −65% at 12 months |
| Reduction in pallor / white patches | No improvement | −61% at 12 months |
| Reduction in stromal hyalinization (fibrosis) | No | Yes, marked |
| Increase in microvascular density | No | Yes, marked |
| Reduction in CD3+ T lymphocytes (autoimmunity) | No | Yes, significant |
| Quality of life (Skindex-29) | No statistical significance | Marked and sustained improvement |
| Flare-ups during follow-up | 3 cases in control group | 0 documented cases |
Why the biopsy is the definitive argument: what cannot be faked
Symptoms can improve due to the placebo effect, stress reduction, or the natural variability of the disease. But the biopsy does not lie. What appears under the microscope, before and after treatment, is objective evidence that no perception bias can falsify.
Significant histological changes at 12 months (2025 Study, Nixarian Institute)
- Reduction in stromal hyalinization: the dense fibrosis characteristic of advanced lichen sclerosus decreases in the tissue sample. This is not controlling symptoms: it is reversing structural damage that was considered irreversible.
- Increase in microvascular density: the tissue forms new blood vessels. Better irrigation means a greater regenerative capacity of the body itself.
- Reduction in CD3+ T lymphocytes: the immune response that destroys vulvar tissue decreases significantly. The protocol modulates the underlying autoimmune disease, not just its visible consequences.
- Greater epidermal thickness and less basal vacuolization: the vulvar epithelium, thinned by years of inflammation, shows clear signs of structural recovery in post-treatment biopsies.
“Corticosteroids inhibit epidermal regeneration. The SVF protocol acts in the opposite direction: it stimulates epithelial thickness and reduces fibrosis.”
Gutiérrez-Ontalvilla et al., Aesthetic Surgery Journal, 2025
Are you a candidate for the Liquenia-SVF protocol? Patient profile for each treatment
Table 3. Recommended patient profile according to treatment.
| Corticosteroids: recommended candidate | Liquenia-SVF Protocol: recommended candidate |
|---|---|
| Recent diagnosis, without previous treatment | Patient who has not responded satisfactorily to 3+ months of clobetasol |
| Mild or moderate forms with good initial response to clobetasol | Moderate-severe VLS with visible fibrosis, stenosis, or significant atrophy |
| Preference for home treatment, without procedures | High symptomatic burden (chronic itching, dyspareunia, fissures) poorly controlled with corticosteroids |
| First line before considering regenerative options | Those who wish to act on the disease at the tissue level, not just symptomatically |
| Maintenance of remission after regenerative treatment | Women concerned about the effects of chronic corticosteroid use on the vulvar epithelium |
Patients with vulvar lichen planus: consult for individual assessment with the team.
Is the Liquenia-SVF protocol safe? Safety comparison
Table 4. Comparative safety profile.
| Safety aspect | Long-term corticosteroids | Liquenia-SVF Protocol |
|---|---|---|
| Serious adverse events | Rare with correct topical doses | ✓ Zero in two published studies, 12-month follow-up |
| Treatment-induced epidermal atrophy | ⚠ Documented with prolonged use (Barnes et al., 2015) | Not observed. The effect is the opposite: regenerative and thickening of the epithelium |
| Discomfort during and after the procedure | None (topical application at home) | Mild sensitivity in the injection and donor area, self-limiting, managed with paracetamol |
| Risk of rejection or allergic reaction | Possible (external pharmaceutical product) | None — 100% the patient’s own tissue |
| Risk of flare-ups when reducing treatment | High documented recurrence rate | Lower flare-up rate observed during 12-month follow-up |
What the Liquenia-SVF protocol cannot yet promise you
Honesty that builds trust. These are the real limits of the treatment.
- It does not cure lichen sclerosus definitively: no current treatment eliminates vulvar lichen sclerosus permanently. The protocol reduces inflammation, reverses fibrosis, and improves symptoms in a sustained manner, but requires continuous follow-up.
- It does not return the labia minora if they have already disappeared: severe structural atrophy did not respond in any of the published studies. This is a limit that any serious team recognizes with transparency.
- Sexual improvement without statistical significance: dyspareunia improved in trend, but sexual dysfunction in lichen sclerosus is multifactorial. It requires a combined approach with pelvic floor physiotherapy, sexology, and psychological support.
- Long-term maintenance data pending: the optimal frequency of booster sessions is still under study.
“My life is back to how it was before. My discomfort disappeared, my intimate relationships have improved, I have no discomfort of any kind, and I feel as I did before the illness. Patricia’s work with stem cells and the diet works very well for me.”
Are corticosteroids no longer enough?
Discover if the Liquenia-SVF protocol is the alternative you have been looking for.
Frequently asked questions about corticosteroids and the Liquenia-SVF protocol
What happens if clobetasol does not work for vulvar lichen sclerosus?
Between 30% and 40% of patients with vulvar lichen sclerosus do not respond satisfactorily to clobetasol propionate 0.05% after three months of treatment. In that case, international clinical guidelines consider second-line treatments. The Liquenia-SVF protocol has demonstrated efficacy precisely in this patient profile, with reductions of 65–77% in symptoms and significant histological changes in biopsy at 12 months.
Is the Liquenia-SVF protocol better than corticosteroids for lichen sclerosus?
They are not comparable treatments: they have different mechanisms of action and are used at different times. Corticosteroids are the correct and necessary first line. The Liquenia-SVF protocol is the second line for those who do not respond to clobetasol or seek to act on the tissue at a regenerative level. In published studies, the protocol demonstrated clear advantages in histological biopsy that corticosteroids cannot offer.
Can corticosteroids and the Liquenia-SVF protocol be used at the same time?
Yes, and it is the recommended approach in published studies. The 2025 study included maintenance with betamethasone dipropionate 0.05% twice a week during post-treatment follow-up. The researchers conclude that they are complementary: corticosteroids control flare-ups and active inflammation, while the protocol works on the regeneration of the underlying tissue.
How many sessions of the Liquenia-SVF protocol do I need?
The 2025 study demonstrated significant improvements with a single session, maintained for 12 months. The 2022 study evaluated two sessions three months apart. In cases with a higher degree of fibrosis or advanced involvement, the literature describes up to three sessions for optimal results. The exact number is determined in the individual assessment with Dr. Gutiérrez-Ontalvilla’s team.
Does the Liquenia-SVF protocol work for vulvar lichen planus?
The protocol acts on the inflammatory and immunological mechanisms that vulvar lichen sclerosus and lichen planus share: T-lymphocyte-mediated autoimmune inflammation, destruction of epithelial tissue, and loss of vascularization. Although published evidence up to 2025 focuses on vulvar lichen sclerosus, the action profile of SVF mesenchymal stem cells is directly relevant. Consult with our team to assess if you are a candidate.
Does the Liquenia-SVF protocol have side effects?
In the two published clinical studies, no serious adverse events were recorded. The only reported effects were mild discomfort in the vulvar injection area and in the fat extraction area — abdomen or thigh — which resolved spontaneously within a few days and were managed only with paracetamol. The use of autologous material eliminates the risk of rejection or allergic reaction.
How long does it take to notice improvement with the Liquenia-SVF protocol?
According to published data, the reduction in itching and burning begins to be noticed in the first one or two months after the session. Improvements in clinical signs — fissures, pallor, white patches, stenosis — were documented at three and six months. Histological changes in biopsy were measured at 12 months. The treatment acts progressively because it regenerates the tissue from within.
Where is the Liquenia-SVF protocol available in Spain?
The Liquenia-SVF protocol is available at the Nixarian Institute in Valencia, directed by Dr. Patricia Gutiérrez-Ontalvilla, MD PhD, lead researcher of the two published clinical studies. She has developed the protocol over more than 10 years of clinical research with histological biopsy. To request a consultation, you can contact the Liquenia team directly.
Scientific references
- Gutiérrez-Ontalvilla P, Giner F, Vidal L, Iborra M. The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate–Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate. Aesthetic Plastic Surgery, 2022. doi:10.1007/s00266-021-02718-1
- Gutiérrez-Ontalvilla P, Gómez Rojas A, Iborra Colomino M, et al. Clinical and Histopathological Investigation of Stromal Vascular Fraction and Nanofat in Vulvar Lichen Sclerosus. Aesthetic Surgery Journal, 2025. doi:10.1093/asj/sjaf148
- Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Saf. 2015;38:493–509.
- Lewis FM et al. British Association of Dermatologists guidelines for the management of lichen sclerosus. Br J Dermatol. 2018;178(4):839–853.
